# EDGAR Filing Document

**Accession Number:** 0001477449
**File Stem:** 0001558370-23-001751
**Filing Date:** 2023-2
**Character Count:** 50819
**Document Hash:** 7d1fe4b2566ccd3965602464b707c085
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-001751.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001558370-23-001751

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230222

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Teladoc Health, Inc.
- **CENTRAL INDEX KEY:** 0001477449
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **IRS NUMBER:** 043705970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37477
- **FILM NUMBER:** 23653169

**BUSINESS ADDRESS:**
- **STREET 1:** 2 MANHATTANVILLE ROAD
- **STREET 2:** SUITE 203
- **CITY:** PURCHASE
- **STATE:** NY
- **ZIP:** 10577
- **BUSINESS PHONE:** 2036352002

**MAIL ADDRESS:**
- **STREET 1:** 2 MANHATTANVILLE ROAD
- **STREET 2:** SUITE 203
- **CITY:** PURCHASE
- **STATE:** NY
- **ZIP:** 10577

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Teladoc, Inc.
- **DATE OF NAME CHANGE:** 20091123

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, District of Columbia 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **February 22, 2023**

**Teladoc Health, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37477** | **04-3705970** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **2 Manhattanville Road, Suite 203** |  |
| **Purchase, New York** | **10577** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**(203) 635-2002**

(Registrant's telephone number, including area code)

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| .<br>|  |  |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | TDOC | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the

Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2

of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended

transition period for complying with any new or revised financial accounting standards provided pursuant to Section

13(a) of the Exchange Act. ☐

------

**Item 2.02.** **Results of Operations and Financial Condition.**

On February 22, 2023, Teladoc Health, Inc. (the "Company") issued a press release relating to its financial results for the fourth quarter and full year 2022. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1.

The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

**Item 9.01.** **Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1\* | [Teladoc Health, Inc. press release, dated February 22, 2023.](tdoc-20230222xex99d1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL).<br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\* Furnished herewith.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | TELADOC HEALTH, INC. | TELADOC HEALTH, INC. |
| Date: February 22, 2023 |  |  |
|  | By: | /s/ Adam C. Vandervoort |
|  | Name: | Adam C. Vandervoort |
|  | Title: | Chief Legal Officer and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](tdoc-20230222xex99d1001.jpg)

**Teladoc Health Reports Fourth Quarter and Full Year 2022 Results** 

&nbsp;&nbsp;&nbsp;&nbsp;● *Fourth quarter revenue grows 15% year-over-year to $637.7 million and full year revenue grows 18% year-over-year to $2,406.8 million* 

&nbsp;&nbsp;&nbsp;&nbsp;● *2022 full year cash flow from operating activities and free cash flow was $189.3 million and $16.5 million, respectively; Cash position of $918.2 million as of December 31, 2022* 

&nbsp;&nbsp;&nbsp;&nbsp;● *Fourth quarter net loss per share of $23.49 and full year net loss per share of $84.60, driven by non-cash goodwill impairment charges of $23.26 per share in fourth quarter and $83.01 per share for full year* 

&nbsp;&nbsp;&nbsp;&nbsp;● *Fourth quarter adjusted EBITDA totaled $94.1 million and full year adjusted EBITDA totaled $246.5 million* 

&nbsp;&nbsp;&nbsp;&nbsp;● *Disclosures expanded to include Teladoc Health Integrated Care segment and BetterHelp segment results* 

**PURCHASE, NY, February 22, 2023**— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the fourth quarter and full year ended December 31, 2022.

"We are pleased with the strong fourth quarter and full year operating results," said Jason Gorevic, CEO of Teladoc Health. "Despite a challenging macro environment, we were able to expand our product offerings and enhance the level of care delivered across our integrated whole-person platform."

Gorevic added, "As we look ahead to 2023, we see a healthy demand for solutions that promise better access and outcomes while lowering the cost of healthcare. Our key strategic priorities remain our whole-person suite of services including our virtual primary care offering - Primary360, our suite of chronic care management solutions, mental health, and continued growth in our BetterHelp consumer brand. We remain committed to a balanced approach to growth and margin which will allow us to invest in key initiatives across our product roadmap."

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Key Financial Data** |  |  |  |  |  |  |
| *($ thousands, unaudited)* |  |  |  |  |  |  |
|  | **Quarter Ended**  | **Quarter Ended**  | **Year over Year** | **Year Ended**  | **Year Ended**  | **Year over Year** |
|  | **December 31,**  | **December 31,**  | **Change** | **December 31,**  | **December 31,**  | **Change** |
|  | **2022** | **2021** |  | **2022** | **2021** |  |
| Revenue | $637709 | $554235 | 15% | $2406840 | $2032707 | 18% |
| Net Loss | $(3810071) | $(10985) | N/M | $(13659531) | $(428793) | N/M |
| Net Loss per share, basic and diluted | $(23.49) | $(0.07) | N/M | $(84.60) | $(2.73) | N/M |
| Adjusted EBITDA (1) | $94094 | $77077 | 22% | $246513 | $267837 | (8)% |

---

*See note (1) in the Notes section that follows.*

*N/M – Not meaningful*

------

**Fourth Quarter 2022**

**Revenue** increased 15% to $637.7 million from $554.2 million in the fourth quarter of 2021. Access fees revenue grew 16% to $553.7 million and other revenue grew 10% to $84.0 million. U.S. Revenues grew 15% to $554.4 million and International revenues grew 17% to $83.3 million.

Revenue increased 6% to $357.1 million for the Teladoc Health Integrated Care ("Integrated Care") segment and increased 29% to $277.0 million for the BetterHelp segment in the fourth quarter of 2022. See note (9) in the Notes section that follows for further information regarding segment reporting.

**Non-cash goodwill impairment charges** of $3.8 billion were recorded in the fourth quarter of 2022. The non-cash charges had no impact on the provision for income taxes.

**Net loss** totaled $3,810.1 million, or ($23.49) per share, for the fourth quarter of 2022, compared to $11.0 million, or ($0.07) per share, for the fourth quarter of 2021. Results for the fourth quarter of 2022 primarily included non-cash goodwill impairment charges of $3,772.8 million, or ($23.26) per share, stock-based compensation expense of $50.8 million, or ($0.31) per share, and amortization of acquired intangibles of $49.0 million, or ($0.30) per share.

Results for the fourth quarter of 2021 included stock-based compensation expense of $61.6 million, or ($0.39) per share, and amortization of acquired intangibles of $45.1 million, or ($0.28) per share.

**Adjusted EBITDA** <sup>(1)</sup> increased 22% to $94.1 million, compared to $77.1 million for the fourth quarter of 2021. Segment adjusted EBITDA increased 31% to $43.7 million for the Integrated Care segment and increased 22% to $52.8 million for the BetterHelp segment in the fourth quarter of 2022.

**GAAP gross margin**, which includes depreciation and amortization, was 68.6% for the fourth quarter of 2022, compared to 67.5% for the fourth quarter of 2021.

**Adjusted gross margin** <sup>(1)</sup> was 70.4% for the fourth quarter of 2022, compared to 68.4% for the fourth quarter of 2021.

**Full Year Ended December 31, 2022**

**Revenue** increased 18% to $2,406.8 million from $2,032.7 million for the year ended December 31, 2022 ("Full-Year 2022"). Access fees revenue grew 21% to $2,103.8 million, and other revenue grew 4% to $303.0 million. U.S. revenues and International revenues each grew 18% to $2,101.0 million and $305.8 million, respectively.

Revenue increased 6% to $1,373.9 million for the Integrated Care segment and increased 41% to $1,019.6 million for the BetterHelp segment for Full-Year 2022.

**Non-cash goodwill impairment charges** of $13.4 billion were recorded for Full-Year 2022. The non-cash charges had no impact on the provision for income taxes.

**Net loss** totaled $13,659.5 million, or ($84.60) per share, for the year ended December 31, 2022, compared to $428.8 million, or ($2.73) per share, for the year ended December 31, 2021. Results for Full-Year 2022 primarily included non-cash impairment charges of $13,402.8 million, or ($83.01) per share, as well as stock-based compensation expense of $217.9 million, or ($1.35) per share, and amortization of acquired intangibles of $196.3 million, or ($1.22) per share.

Results for the year ended December 31, 2021 included stock-based compensation expense of $302.6 million, or ($1.93) per share, amortization of acquired intangibles of $178.9 million, or

------

($1.14) per share, loss on extinguishment of debt of $43.7 million, or ($0.28) per share, and income taxes charges of $44.1 million, or ($0.28) per share.

**Adjusted EBITDA** <sup>(1)</sup> decreased 8% to $246.5 million compared to $267.8 million for the year ended December 31, 2021. Segment adjusted EBITDA for the Integrated Care segment was $135.2 million for Full-Year 2022, versus $144.0 million in the prior year. Segment adjusted EBITDA for the BetterHelp segment was $114.1 million for Full-Year 2022, versus $121.7 million in the prior year.

**GAAP gross margin**, which includes depreciation and amortization, was 67.8% for the Full-Year 2022, compared to 67.2% for the full year 2021.

**Adjusted gross margin** <sup>(1)</sup> was 69.1% for the Full-Year 2022 compared to 68.0% in the prior year.

**Capex and Cash Flow**

Cash flow from operations was $65.5 million and $189.3 million in the fourth quarter and full year of 2022, respectively, as compared to $83.2 million and $194.0 million in the fourth quarter and full year of 2021, respectively. Capitalized expenditures and capitalized software (together, "Capex") was $53.9 million in the fourth quarter of 2022 and $172.8 million for the full year 2022, as compared to $22.9 million in the fourth quarter of 2021 and $63.9 million for the full year 2021. Free cash flow was $11.7 million in the fourth quarter of 2022 and $16.5 million for the full year 2022, as compared to $60.3 million in the fourth quarter of 2021 and $130.1 million for the full year 2021.

**Financial Outlook**

Teladoc Health provides an outlook based on current market conditions and expectations and what we know today. Based on what we know today, we believe our outlook ranges provide a reasonable baseline for 2023 financial performance.

**For the first quarter of 2023, we expect:**

---

| | |
|:---|:---|
|  | **1Q 2023 Outlook Range** |
| Revenue | $610 - $625 million |
| Adjusted EBITDA | $42 - $50 million |
| Net loss per share | ($0.55) - ($0.45) |
| U.S. Integrated Care Members (3) | 84 - 85 million |

---

**For the full year 2023, we expect:** 

---

| | |
|:---|:---|
|  | **Full Year 2023 Outlook Range** |
| Revenue | $2,550 - $2,675 million |
| Adjusted EBITDA | $275 - $325 million |
| Net loss per share | ($1.75) - ($1.25) |
| U.S. Integrated Care Members (3) | 84 - 86 million |

---

*See note (3) in the Notes section that follows.*

------

**Earnings Conference Call**

The fourth quarter and full year 2022 earnings conference call and webcast will be held Wednesday, February 22, 2023 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-844-200-6205 for U.S. participants, or 1-929-526-1599 for international participants, and referencing Conference ID Number: 033061; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link, and will remain available for approximately 90 days.

**About Teladoc Health**

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person's health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; and (viii) the impact of the COVID-19 pandemic on our operations, demand for our services and general economic conditions, as well as orders, directives and legislative action by local, state, federal and foreign governments in response to the spread of COVID-19. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no

------

obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Revenues**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Quarter Ended**  | **Quarter Ended**  | **Year over Year** | **Year Ended**  | **Year Ended**  | **Year over Year** |
| *($ thousands)* | **December 31,**  | **December 31,**  | **Change** | **December 31,**  | **December 31,**  | **Change** |
|  | **2022** | **2021** |  | **2022** | **2021** |  |
| **Revenue by Type** |  |  |  |  |  |  |
| Access fees | $553668 | $478081 | 16% | $2103814 | $1740170 | 21% |
| Other (2) | 84041 | 76154 | 10% | 303026 | 292537 | 4% |
| Total Revenue | $637709 | $554235 | 15% | $2406840 | $2032707 | 18% |
| **Revenue by Geography** |  |  |  |  |  |  |
| U.S. Revenue | $554416 | $482895 | 15% | $2101015 | $1774024 | 18% |
| International Revenue | 83293 | 71340 | 17% | 305825 | 258683 | 18% |
| Total Revenue | $637709 | $554235 | 15% | $2406840 | $2032707 | 18% |

---

*See note (2) in the Notes section that follows.*

**Summary Operating Metrics (6)** 

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended**  | **Year Ended**  | **Year over Year** |
| *(millions, except revenue per member)* | **December 31,**  | **December 31,**  | **Change** |
|  | **2022** | **2021** |  |
| U.S. Integrated Care Members (3) | 83.3 | 77.5 | 7% |
| BetterHelp Paying Users (4) | 0.419 | 0.307 | 37% |
| Chronic Care Program Enrollment (5) | 1.019 | 0.878 | 16% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Quarter Ended**  | **Quarter Ended**  | | **Year Ended**  | **Year Ended**  | |
|  | **December 31,**  | **December 31,**  | **Year over Year**<br>**Change** | **December 31,**  | **December 31,**  | **Year over Year**<br>**Change** |
|  | **2022** | **2021** |  | **2022** | **2021** |  |
| Total Visits | 4.8 | 4.4 | 8% | 18.5 | 15.4 | 20% |
| Average Revenue Per U.S. Integrated Care Member (7) | $1.44 | $1.46 | (2)% | $1.42 | $1.46 | (2)% |

---

*See notes (3), (4), (5), (6), and (7) in the Notes section that follows.*

------

**TELADOC HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except share and per share data, unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter Ended December 31,**  | **Quarter Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenue | $637709 | $554235 | $2406840 | $2032707 |
| Expenses: |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue (exclusive of depreciation and amortization, <br>which is shown separately below) | 188873 | 174985 | 743987 | 650258 |
| &nbsp;&nbsp;Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and marketing | 146443 | 112988 | 623536 | 416726 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales | 56278 | 59330 | 227172 | 250581 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology and development | 82930 | 72867 | 333629 | 311884 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 119845 | 118603 | 449855 | 438007 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition, integration, and transformation costs | 6627 | 4559 | 15620 | 26643 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs | 3738 | 0  | 7416 | 0  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 75716 | 52332 | 256027 | 204239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | 3772811  | 0  | 13402812 | 0  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 4453261 | 595664 | 16060054 | 2298338 |
| Loss from operations | (3815552) | (41429) | (13653214) | (265631) |
| Loss on extinguishment of debt | 0  | 20 | 0  | 43748 |
| Other (income) expense, net | (1749) | 405 | 859 | (5088) |
| Interest (income) expense, net | (1892) | 18872 | 9270 | 80365 |
| Net loss before provision for income taxes | (3811911) | (60726) | (13663343) | (384656) |
| Provision for income taxes | (1840) | (49741) | (3812) | 44137 |
| Net loss | $(3810071) | $(10985) | $(13659531) | $(428793) |
| Net loss per share, basic and diluted | $(23.49) | $(0.07) | $(84.60) | $(2.73) |
| Weighted-average shares used to compute basic <br>and diluted net loss per share | 162169564 | 159944335 | 161457123 | 156939349 |

---

**Stock-based Compensation Summary**

Compensation costs for stock-based awards were classified as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter Ended**  | **Quarter Ended**  | **Year Ended**  | **Year Ended**  |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| Cost of revenue (exclusive of depreciation and amortization, <br>which is shown separately) | $1474 | $1970 | $6468 | $8280 |
| Advertising and marketing | 3561 | 3811 | 14083 | 18952 |
| Sales | 9337 | 13837 | 43183 | 71475 |
| Technology and development | 14461 | 18226 | 64577 | 95561 |
| General and administrative | 21921 | 23771 | 89541 | 108318 |
| Total stock-based compensation expense (8) | $50754 | $61615 | $217852 | $302586 |

---

*See note (8) in the Notes section that follows.*

------

**Operating Results by Segment (see note (9) in the Notes section that follows)**

The following table presents operating results by reportable segment for the periods indicated:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Quarter Ended**  | **Quarter Ended**  | **Year over Year** | **Year over Year** | **Year Ended**  | **Year Ended**  | **Year over Year** | **Year over Year** |
| *($ thousands, unaudited)* | **December 31,**  | **December 31,**  | **Change** | **Change** | **December 31,**  | **December 31,**  | **Change** | **Change** |
|  | **2022** | **2021** |  |  | **2022** | **2021** |  |  |
| **Teladoc Health Integrated Care** |  |  |  |  |  |  |  |  |
| Revenue | $357100 | $337288 | 6 | % | $1373900 | $1300878 | 6 | % |
| Adjusted EBITDA | $43686 | $33450 | 31 | % | $135153 | $144021 | (6) | % |
| Adjusted EBITDA Margin % | 12.2% | 9.9% | 232 | bps | 9.8% | 11.1% | (123) | bps |
| **BetterHelp** |  |  |  |  |  |  |  |  |
| Therapy Services | $274495 | $213329 | 29 | % | $1012574 | $720270 | 41 | % |
| Other Wellness Services | 2513 | 675 | 272 | % | 7072 | 968 | 631 | % |
| Total Revenue | $277008 | $214004 | 29 | % | $1019646 | $721238 | 41 | % |
| Adjusted EBITDA | $52846 | $43183 | 22 | % | $114116 | $121702 | (6) | % |
| Adjusted EBITDA Margin % | 19.1% | 20.2% | (110) | bps | 11.2% | 16.9% | (568) | bps |

---

**Operating Results by Segment by Quarter** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **4Q** | **1Q** | **2Q** | **3Q** | **4Q** |
| *($ thousands, unaudited)* | **2021** | **2022** | **2022** | **2022** | **2022** |
| **Teladoc Health Integrated Care** |  |  |  |  |  |
| Revenue | $337288 | $332384 | $341599 | $342817 | $357100 |
| Adjusted EBITDA | $33450 | $23267 | $29320 | $38880 | $43686 |
| Adjusted EBITDA Margin % | 9.9% | 7.0% | 8.6% | 11.3% | 12.2% |
| **BetterHelp** |  |  |  |  |  |
| Therapy Services | $213329 | $229117 | $245754 | $263208 | $274495 |
| Other Wellness Services | 675 | 1057 | 1560 | 1942 | 2513 |
| Total Revenue | $214004 | $230174 | $247314 | $265150 | $277008 |
| Adjusted EBITDA | $43183 | $30098 | $20022 | $11150 | $52846 |
| Adjusted EBITDA Margin % | 20.2% | 13.1% | 8.1% | 4.2% | 19.1% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Summary Operating Metrics** | **4Q** | **1Q** | **2Q** | **3Q** | **4Q** |
| *(millions, except revenue per member)* | **2021** | **2022** | **2022** | **2022** | **2022** |
| U.S. Integrated Care Members (3) | 77.5 | 79.2 | 80.3 | 81.9 | 83.3 |
| BetterHelp Paying Users (4) | 0.351 | 0.382 | 0.408 | 0.437 | 0.450 |
| Chronic Care Program Enrollment (5) | 0.878 | 0.913 | 1.005 | 0.993 | 1.019 |
| Average Revenue Per U.S. Integrated Care Member (7) | $1.46 | $1.41 | $1.43 | $1.40 | $1.44 |

---

*See notes (3), (4), (5), and (7) in the Notes section that follows.*

------

**TELADOC HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands, unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,**  | **Year Ended December 31,**  |
|  | **2022** | **2021** |
| Cash flows from operating activities: |  |  |
| Net loss | $(13659531) | $(428793) |
| Adjustments to reconcile net loss to net cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | 13402812 | 0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 256027 | 204239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation of rental equipment | 2859 | 3333 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use assets | 11757 | 12049 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for doubtful accounts | 15398 | 16941 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 217852 | 302586 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (7840) | 41800 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion of interest | 3345 | 61253 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | 0 | 40652 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment | 0 | (5901) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 7584 | (3845) |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (61641) | (17510) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (41081) | (31090) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 14800 | (19494) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | (27767) | (3547) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 1876 | 1188 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 61217 | 18175 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | (12290) | (4675) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 15240 | 20554 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (11525) | (16532) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 200 | 2607 |
| Net cash provided by operating activities | 189292 | 193990 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (16480) | (8534) |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalized software | (156284) | (55400) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from marketable securities | 2507 | 50000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of investment | 0 | 10901 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions of business, net of cash acquired | 0 | (78663) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 2514 | 8715 |
| Net cash used in investing activities | (167743) | (72981) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net proceeds from the exercise of stock options | 5884 | 25781 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of 2022 Notes | 0 | (139) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from advances from financing companies | 11873 | 15275 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment against advances from financing companies | (15020) | (16050) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from employee stock purchase plan | 6501 | 16810 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash received for withholding taxes on stock-based compensation, net | 124 | 3422 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | (2865) | (4152) |
| Net cash provided by financing activities | 6497 | 40947 |
| Net decrease in cash and cash equivalents | 28046 | 161956 |
| Foreign exchange difference | (3344) | (1800) |
| Cash and cash equivalents at beginning of the period | 893480 | 733324 |
| Cash and cash equivalents at end of the period | $918182 | $893480 |

---

------

The following table presents the selected cash flow information for the following quarters (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Quarter Ended** | **Quarter Ended** |
|  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** |
| Consolidated Statements of Cash Flows - Summary |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | $65549 | $83208 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (53891) | (20075) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 4381 | 6624 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange difference | 2512 | (105) |
| Net decrease in cash and cash equivalents | $18551 | $69652 |

---

**TELADOC HEALTH, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands, except share and per share data, unaudited)**

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2022** | **December 31,** <br>**2021** |
| Assets |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $918182 | $893480 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 0 | 2537 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance of $14,800 and $12,384, respectively | 210554 | 168956 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 56342 | 73079 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 130310 | 87387 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1315388 | 1225439 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 29641 | 27234 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 1073190 | 14504174 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 1836765 | 1910278 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease - right-of-use assets | 41831 | 46780 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 48540 | 20703 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $4345355 | $17734608 |
| Liabilities and stockholders' equity |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $47690 | $47257 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 168693 | 102933 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 81554 | 91941 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue-current | 90457 | 75569 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advances from financing companies | 11375 | 13313 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 399769 | 331013 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 1618 | 1492 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 38042 | 41773 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue, net of current portion | 3872 | 3834 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advances from financing companies, net of current portion | 8082 | 9291 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes, net | 50939 | 75777 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible senior notes, net | 1535288 | 1225671 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; 300,000,000 shares authorized; 162,840,360 shares and 160,469,325 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | 163 | 160 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 17358645 | 17473336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (15008287) | (1421454) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (42776) | (6285) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 2307745 | 16045757 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $4345355 | $17734608 |

---

------

**Non-GAAP Financial Measures:**

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we use adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA and free cash flow, which are non-GAAP financial measures, to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.

Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which is shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue.

EBITDA consists of net loss before interest; other (income) expense, net, including foreign exchange gain or loss; provision for income taxes; depreciation and amortization; goodwill impairment; and loss on extinguishment of debt. Adjusted EBITDA consists of net loss before interest (income) expense, net; other (income) expense, net, including foreign exchange gain or loss; provision for income taxes; depreciation and amortization; goodwill impairment; loss on extinguishment of debt; stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs.

Free cash flow is net cash (used in) provided by operating activities less capital expenditures and capitalized software development costs. Free cash flow reflects an additional way of viewing our liquidity that, we believe, when viewed with GAAP results, provides management, investors and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA and free cash flow may vary from that of others in our industry. None of adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA nor free cash flow should be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash provided by operating activities or any other performance measures derived in accordance with GAAP.

Adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA and free cash flow have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

● adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;

● adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;

● EBITDA and adjusted EBITDA do not reflect goodwill impairment;

● EBITDA and adjusted EBITDA do not reflect the interest (income) expense, net;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● EBITDA and adjusted EBITDA eliminate the impact of the provision for income taxes on our results of operations;

● EBITDA and adjusted EBITDA do not reflect the loss on extinguishment of debt;

● EBITDA and adjusted EBITDA do not reflect other (income) expense, net;

● adjusted EBITDA does not reflect significant restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;

● adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management (CRM) and enterprise resource planning (ERP) systems. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities;

● adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and

● other companies in our industry may calculate adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA differently than we do, limiting the usefulness of these measures as comparative measures.

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA, and free cash flow along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA, and free cash flow should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

------

The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively:

**Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin**

**(In thousands, unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter Ended** | **Quarter Ended** | **Year Ended**  | **Year Ended**  |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenue | $637709 | $554235 | $2406840 | $2032707 |
| Cost of revenue (exclusive of depreciation and amortization, which is shown separately below) | (188873) | (174985) | (743987) | (650258) |
| Depreciation and amortization of intangible assets | (11109) | (5406) | (30773) | (16546) |
| Gross Profit | 437727 | 373844 | 1632080 | 1365903 |
| Depreciation and amortization of intangible assets | 11109 | 5406 | 30773 | 16546 |
| Adjusted gross profit | $448836 | $379250 | $1662853 | $1382449 |
| Gross margin | 68.6% | 67.5% | 67.8% | 67.2% |
| Adjusted gross margin | 70.4% | 68.4% | 69.1% | 68.0% |

---

The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to EBITDA and adjusted EBITDA:

**Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA**

**(In thousands, except for outlook data, unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Quarter Ended** | **Quarter Ended** | **Year Ended**  | **Year Ended**  | **Outlook in millions (10)** | **Outlook in millions (10)** |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  | **First Quarter** | **Full Year** |
|  | **2022** | **2021** | **2022** | **2021** | **2023** | **2023** |
| Net loss | $(3810071) | $(10985) | $(13659531) | $(428793) | $(90) - ($73) | $(288) - ($206) |
| Adjustments: |  |  |  |  |  |  |
| Goodwill impairment | 3772811 | 0 | 13402812 | 0 |  |  |
| Loss on extinguishment of debt | 0 | 20 | 0 | 43748 |  |  |
| Other (income) expense , net | (1749) | 405 | 859 | (5088) |  |  |
| Interest (income) expense, net | (1892) | 18872 | 9270 | 80365 |  |  |
| Provision for income taxes | (1840) | (49741) | (3812) | 44137 |  |  |
| Depreciation and amortization | 75716 | 52332 | 256027 | 204239 |  |  |
| Total Adjustments | 3843046 | 21888 | 13665156 | 367401 | 53 - 80 | 231 - 363 |
| **Consolidated EBITDA** | **32975** | **10903** | **5625** | **(61392)** | **(20) - (10)** | **25 - 75** |
| Adjustments: |  |  |  |  |  |  |
| Stock-based compensation | 50754 | 61615 | 217852 | 302586 |  |  |
| Acquisition, integration, and transformation costs | 6627 | 4559 | 15620 | 26643 |  |  |
| Restructuring costs | 3738 | 0 | 7416 | 0 |  |  |
| Total Adjustments | 61119 | 66174 | 240888 | 329229 | 52 - 70 | 200 - 300 |
| **Consolidated Adjusted EBITDA** | $**94094** | $**77077** | $**246513** | $**267837** | $**42 - $50** | $**275 - $325** |
| **Segment Adjusted EBITDA** |  |  |  |  |  |  |
| &nbsp;&nbsp;Teladoc Health Integrated Care | $43686 | $33450 | $135153 | $144021 |  |  |
| &nbsp;&nbsp;BetterHelp | 52846 | 43183 | 114116 | 121702 |  |  |
| &nbsp;&nbsp;Other | (2438) | 444 | (2756) | 2114 |  |  |
| **Consolidated Adjusted EBITDA** | $**94094** | $**77077** | $**246513** | $**267837** |  |  |

---

*See note (10) in the Notes section that follows.*

------

**Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA**

**(In thousands, except for outlook data, unaudited)**

---

| | | | |
|:---|:---|:---|:---|
|  | **1Q** | **2Q** | **3Q** |
|  | **2022** | **2022** | **2022** |
| Net loss | $(6674523) | $(3101461) | $(73476) |
| Add: |  |  |  |
| Goodwill impairment | 6600000 | 3030000  | 0  |
| Other (income) expense, net | (724) | 1760  | 1571  |
| Interest expense, net | 5480  | 4337  | 1346  |
| Provision for income taxes | 388  | (1188) | (1171) |
| Depreciation and amortization | 58933  | 59371  | 62008  |
| **Consolidated EBITDA** | **(10446)** | **(7181)** | **(9722)** |
| Stock-based compensation | 60436  | 51000  | 55662  |
| Acquisition, integration, and transformation costs | 4507  | 2892  | 1594  |
| Restructuring costs | 0  | 0  | 3677  |
| **Consolidated Adjusted EBITDA** | $**54497** | $**46711** | $**51211** |
| Segment Adjusted EBITDA |  |  |  |
| &nbsp;&nbsp;Teladoc Health Integrated Care | $23267 | $29320 | $38880 |
| BetterHelp | 30098 | 20022 | 11150 |
| Other | 1132 | (2631) | 1181 |
| **Consolidated Adjusted EBITDA** | $**54497** | $**46711** | $**51211** |

---

The following is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow:

**Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow**

**(In thousands, unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter Ended**  | **Quarter Ended**  | **Year Ended**  | **Year Ended**  |
|  | **December 31,**  | **December 31,**  | **December 31,**  | **December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| Net cash provided by operating activities | $65549 | $83208 | $189292 | $193990 |
| Capital expenditures | (6194) | (2922) | (16480) | (8534) |
| Capitalized software | (47697) | (19999) | (156284) | (55400) |
| Free Cash Flow | $11658 | $60287 | $16528 | $130056 |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;1. A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these non-GAAP measures is also included under the heading "Non-GAAP Financial Measures."

&nbsp;&nbsp;&nbsp;&nbsp;2. Other revenue now combines what had been separately reported previously as visit fees and other revenue.

&nbsp;&nbsp;&nbsp;&nbsp;3. U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.

&nbsp;&nbsp;&nbsp;&nbsp;4. BetterHelp Paying Users represent the average number of global monthly paid users of our BetterHelp therapy services during the applicable period.

&nbsp;&nbsp;&nbsp;&nbsp;5. Chronic Care Program Enrollment represents the total of enrollees across our suite of chronic care programs at the end of a given period.

&nbsp;&nbsp;&nbsp;&nbsp;6. At December 31, 2022, U.S. Paid Membership was 58.4 million, U.S. Visit Fee Only Access was 24.8 million, and Unique Chronic Care Members was 0.805 million, each calculated consistent with the definitions previously provided in the third quarter 2022 earnings release.

------

&nbsp;&nbsp;&nbsp;&nbsp;7. Average revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 3) during the applicable period. Approximately 20% of total Integrated Care revenues relate to international and hospital and health systems for which membership is not considered as a management metric.

&nbsp;&nbsp;&nbsp;&nbsp;8. Excluding the amount capitalized related to software development projects.

&nbsp;&nbsp;&nbsp;&nbsp;9. ASC Subtopic 280-10, "Segment Reporting," establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance. The Company's Chief Executive Officer is the CODM and is responsible for reviewing financial information presented on segment basis for purposes of making operating decisions and assessing financial performance.

The CODM measures and evaluates segments based on segment operating revenues together with Adjusted EBITDA.

Operating revenues and expenses directly associated with each segment are included in determining its operating results. Other expenses that are not directly attributable to a particular segment are allocated based upon methodologies, including the following: revenue, headcount, time and other relevant usage measures, and/or a combination of such. Segments do not record intersegment revenues, and, accordingly, there is none to be reported. The accounting policies for segment reporting are the same as for the Company as a whole.

The Company has two segments: Teladoc Health Integrated Care ("Integrated Care") and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis.

Other includes certain revenues, expenses and charges not related to ongoing segment operations.

&nbsp;&nbsp;&nbsp;&nbsp;10. We have not provided a full line-item reconciliation for net loss to EBITDA or adjusted EBITDA outlook because we do not provide outlook on the individual reconciling items between net loss, EBITDA, and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as goodwill impairment, stock-based compensation and the related tax impact, provision for income taxes, acquisition, integration, and transformation costs, and restructuring costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure outlook is not available without unreasonable effort.

**Investors:**<br>Patrick Feeley

914-265-7925

IR@teladochealth.com

**Media:**

Chris Stenrud

860-491-8821

pr@teladochealth.com

------